Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD7503
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
AZD7503 is an investigational drug developed by AstraZeneca for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and ability to reduce harmful substances in the liver. The drug is administered via subcutaneous injection. Mechanistically, AZD7503 acts by knocking down hepatic HSD17B13 mRNA expression—a target implicated in the pathogenesis of NAFLD/NASH—suggesting it may function as an RNA-based therapy or antisense oligonucleotide targeting HSD17B13[6][1][5].
- Other names
- AZD7503AZD-7503AZD 7503ION455ION-455ION 455
02
Targets
HSD17B13 (17β-Hydroxysteroid Dehydrogenase Type 13)
Beyond the preview
Go deeper on AZD7503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD7503.